Tolerability of 3-day, once-daily azithromycin suspension versus standard treatments for community-acquired paediatric infectious diseases

Authors: Treadway G.1; Reisman A.

Source: International Journal of Antimicrobial Agents, Volume 18, Number 5, November 2001 , pp. 427-431(5)

Publisher: Elsevier

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Keywords: Azithromycin; Safety; Paediatric; Macrolide; beta-Lactam; Infectious diseases

Language: English

Document Type: Research article

DOI: 10.1016/S0924-8579(01)00439-3

Affiliations: 1: Pfizer Pharmaceuticals Group, Pfizer Inc., 235 East 42nd Street, 10017-5755, New York, NY, USA

This article is hosted on another website.

You may be required to register, activate a subscription or purchase the article before you can obtain the full text.

Proceed

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A